The relation between distant metastasis and genetic change type in stage IV lung adenocarcinoma patients at diagnosis
Authors:
- Sinem ErminSESinem Ermin
- Özgür BatumÖBÖzgür Batum
- Merve Saka GüvençMGMerve Saka Güvenç
- Gülden DinizGDGülden Diniz
- Aysu AyrancıAAAysu Ayrancı
- Kadri Murat ErdoğanKEKadri Murat Erdoğan
- Nur YücelNYNur Yücel
- Eylem YıldırımEYEylem Yıldırım
- Taha Reşid ÖzdemirTÖTaha Reşid Özdemir
- Alev Gülşah HacarAHAlev Gülşah Hacar
- Filiz GüldavalFGFiliz Güldaval
- Altuğ KoçAKAltuğ Koç
- 1 February 2021
- journal article
- research article
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 15 (2) , 196-202
Abstract
Introduction Brain metastasis prevalence is higher in patients with positive epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) and C-ROS oncogene 1 (ROS-1) fusion change in lung adenocarcinoma. Objectives The purpose of our study is to investigate the relation between the genetic change type and the initial distant metastasis in stage IV lung adenocarcinoma patients with genetic changes. Methods The study was conducted between January 2007 and December 2018 in a retrospective fashion with patients who had lung cancer diagnosed as stage IV adenocarcinoma. The relation between genetic mutation change (EGFR, ALK or ROS-1) and distant metastasis was analysed. Results A total of 845 patients were included in the study. The median age was 62 (28-88). It was determined that lung and pleura metastases were more frequent at a significant level in patients with positive EGFR mutation (P = 0.032,P = 0.004, respectively). In patients with positive ALK fusion change, pleura metastasis was determined to be more frequent (P = 0.001). Multiple metastases were determined to be significantly more in patients with positive ALK fusion change than single metastasis (P = 0.02). Conclusion In patients with EGFR mutant lung adenocarcinoma, lung and pleura metastasis is more frequent and pleura metastasis is more frequent in ALK positive adenocarcinoma. Additionally, multiple organ metastases are higher in ALK positive lung adenocarcinoma.Keywords
This publication has 12 references indexed in Scilit:
- ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomesecancermedicalscience, 2019
- Relationship between EGFR mutation and computed tomography characteristics of the lung in patients with lung adenocarcinomaThoracic Cancer, 2018
- CT-pathologic correlation in lung adenocarcinoma and squamous cell carcinomaMedicine, 2018
- Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancerLung Cancer, 2018
- The role of the ALK receptor in cancer biologyAnnals of Oncology, 2016
- EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scanMedical Oncology, 2015
- Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium ExperienceJournal of Thoracic Oncology, 2015
- EGFR Mutation and Brain Metastasis in Pulmonary AdenocarcinomasJournal of Thoracic Oncology, 2014
- Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancerCancer, 2012
- EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancerNeuro-Oncology, 2010